# Jazz Pharmaceuticals

markets Epidiolex, the FDA-approved plant-derived CBD drug for severe childhood epilepsy, reporting 15% year-on-year sales growth in Q1 2026 as part of 19% overall company revenue growth.

Source: https://en.bioecon.ru/companies/jazz-pharmaceuticals/
Updated: 2026-07-03

- Country: Ireland
- Ticker: JAZZ

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $250 million in Epidiolex/Epidyolex net product sales in Q1 2026, a 15% increase year-on-year | https://finance.yahoo.com/sectors/healthcare/articles/jazz-pharmaceuticals-plc-jazz-cbd-121554621.html, https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-first-quarter-2026-financial, https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm |
| Revenue | $1.1 billion total revenue in Q1 2026, a 19% increase year-on-year | https://finance.yahoo.com/sectors/healthcare/articles/jazz-pharmaceuticals-plc-jazz-cbd-121554621.html, https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-first-quarter-2026-financial, https://www.sec.gov/Archives/edgar/data/1232524/000123252426000024/a1q26financialpr.htm |
| Revenue | $292.1 million in Epidiolex/Epidyolex net product sales in Q2 2026, a 16% increase year-on-year | https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-second-quarter-2026-financial |
| Revenue | $1.2083 billion total revenue in Q2 2026 | https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-second-quarter-2026-financial |
| Production site | Manufacturing and development facility in Athlone, Ireland; manufacturing facility in Kent Science Park, U.K.; manufacturing plant in Villa Guardia, Italy | http://www.jazzpharma.com/sites/jazzpharmaceuticals/files/2026-06/2025_Jazz_Pharmaceuticals_CSSI_Report_F.pdf, https://www.jazzpharma.com/medicines/manufacturing |
| Regulatory approval | FDA-approved for treatment of seizures associated with LGS, DS, and TSC in patients 1 year of age and older; approved in other international markets including Europe, U.K., Canada, Israel, Australia, Switzerland, Taiwan, and New Zealand | https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-research-epidiolexr-cannabidiol-and, https://www.epidiolex.com/, https://www.marketscreener.com/news/jazz-pharmaceuticals-quarterly-report-for-quarter-ending-march-31-2026-form-10-q-ce7f58ddd88ef025 |
| Certification | Internal manufacturing sites certified under ISO 45001 and ISO 14001:2015 standards | http://www.jazzpharma.com/sites/jazzpharmaceuticals/files/2026-06/2025_Jazz_Pharmaceuticals_CSSI_Report_F.pdf |

Independent sources: epidiolex.com, finance.yahoo.com, investor.jazzpharma.com, marketscreener.com, sec.gov

## Technologies

- [Biosynthetic cannabinoids (CBD & THC)](https://en.bioecon.ru/technology/biosynthetic-cannabinoids-cbd-thc/)